Swiss CRO Psi is amping up its presence in Italy, the latest expansion for a clinical trial outfit looking to meet demand around the globe.
As research universities around the world look to put their labs to lucrative use by launching CROs, Duke University has nailed down another development deal, teaming up with the International Stem Cell Corporation on a Parkinson's disease treatment.
After months of regulatory woes and declining demand, Lonza is planning to cut two-thirds of its staff at a Massachusetts biologics plant, part of the CMO's overall effort to restructure and adapt to a changing market for commercial manufacturing.
PPD has acquired Pennsylvania's Acurian, folding the company's clinical trial patient enrollment and retention services into its expanding eClinical operation.
Speaking to local business leaders in Research Triangle Park, Quintiles CEO Tom Pike said the life sciences' industry's biggest obstacle is comfort, as long-running biases in medicine can stave off innovation.
Cresset, a British provider of drug-discovery services, has faith in the market for early-phase work, and the company has expanded its staff and headquarters to prepare for an uptick in demand.
Switzerland's Psi is reaching into India's clinical research market, opening up shop in the country and continuing its global expansion.
Kansas CRO Vince & Associates, fresh from its private equity buyout, has expanded its endoscopy capabilities, beefing up its technology to attract more early-phase studies of gastrointestinal therapies.
High employee turnover rates have long been a fact of life in the CRO world, but more and more companies are being proactive, amping up their bonus offerings to lure and retain talent, according to study.
The FDA is encouraging drugmakers to embrace new methods of monitoring for clinical trials, and Icon is betting its latest offering can streamline how sponsors deal with study sites and save money in the process.
Now that the FDA is encouraging drugmakers to consider risk-based monitoring for clinical trials, CROs that have already invested in adaptive trials could stand to benefit.
After months of fretting over API capacity, Boehringer Ingelheim is planning to shutter en masse its Petersburg, VA, commercial plant, putting 240 employees out of a job.
Bracket, the pharma contracting arm of Express Scripts, is now the property of Parthenon Capital Partners, the latest private equity takeover in a fast-consolidating industry.
They don't make compounds like the used to--or at least at the same rate. And with fewer and fewer early-stage molecules moving through pipelines, some discovery-focused CROs have been left in the lurch.
WuXi PharmaTech, China's largest CRO, is counting on the burgeoning drug development market in its home country to deliver a big 2013, stretching its annual revenue guidance after another quarterly boost.
Quintiles is back on the buyer's block for the first time since going public, agreeing to scoop up oncology-focused CRO Novella Clinical for an undisclosed sum.
Bristol-Myers Squibb is calling it quits on a depression drug it was working on with Albany Molecular Research, and investors sent the contractor's shares into a plunge as its CEO preached patience.
Covance has launched a managed markets service platform designed to help its biopharma and medical device clients deal with managed care organizations, group purchasing outfits, federal and state programs and wholesalers.
CRO Icon has signed a deal with the National Taiwan University Hospital, lending its weight in clinical research to help make local trials faster and more reliable.
Taiwanese contract manufacturer ScinoPharm and Chinese CRO Sundia MediTech are pooling their resources to cash in on the demand for outsourced services in China.